 Mirati Therapeutics Inc MRTX shares are trading lower by 12.18 to 43.55 during Thursdays session after multiple analysts downgraded their ratings on the stock and lowered their price targets. Shares are also lower on continued weakness after the company announced late-breaking results evaluating concurrent adagrasib and pembrolizumab in first-line advancedmetastatic non-small cell lung cancer. 